Janus Henderson Group PLC Purchases 193,688 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

Janus Henderson Group PLC raised its position in Ascendis Pharma A/S (NASDAQ:ASND) by 4.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,380,382 shares of the biotechnology company’s stock after acquiring an additional 193,688 shares during the period. Janus Henderson Group PLC owned approximately 0.07% of Ascendis Pharma A/S worth $602,910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in ASND. Virtus ETF Advisers LLC grew its holdings in Ascendis Pharma A/S by 3.9% during the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 100 shares in the last quarter. Legato Capital Management LLC boosted its position in shares of Ascendis Pharma A/S by 7.5% in the fourth quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 134 shares during the period. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 394.0% during the fourth quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Ascendis Pharma A/S during the 3rd quarter worth approximately $30,000. Finally, GAMMA Investing LLC increased its holdings in Ascendis Pharma A/S by 58.0% during the 4th quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 214 shares during the period.

Ascendis Pharma A/S Stock Down 5.1 %

Shares of ASND opened at $151.25 on Friday. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $183.00. The stock has a market capitalization of $9.22 billion, a P/E ratio of -21.30 and a beta of 0.41. The firm has a fifty day simple moving average of $156.12 and a two-hundred day simple moving average of $141.46.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The firm had revenue of $123.97 million during the quarter, compared to analysts’ expectations of $98.56 million. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. The Goldman Sachs Group boosted their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Cantor Fitzgerald lifted their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an “overweight” rating in a research report on Tuesday, February 25th. Royal Bank of Canada increased their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, May 2nd. Morgan Stanley upgraded Ascendis Pharma A/S from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $180.00 to $250.00 in a research report on Monday, May 5th. Finally, Wedbush upped their price objective on Ascendis Pharma A/S from $181.00 to $212.00 and gave the stock an “outperform” rating in a report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $216.07.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.